Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ram Yogev

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
AIDS Research and Human Retroviruses|March 11, 2008
Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremiaWilliam Borkowsky, Ram Yogev, Petronella Muresan, et al.
Pediatrics|February 3, 2005
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected childrenRita J Jeremy, Soyeon Kim, Molly Nozyce, et al.
Pediatrics|March 18, 2005
The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxisSharon Nachman, Philimon Gona, Wayne Dankner, et al.
The Pediatric Infectious Disease Journal|December 25, 2008
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patientsJennifer R King, Edward P Acosta, Ram Yogev, et al.
The Pediatric Infectious Disease Journal|May 18, 2016
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young AdultsMarc Foca, Ram Yogev, Andrew Wiznia, et al.
Pediatrics|March 12, 2008
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjectsXavier Saez-Llorens, Avy Violari, Dalubuhle Ndiweni, et al.
AIDS (London, England)|December 22, 2007
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week resultsEllen G Chadwick, Edmund V Capparelli, Ram Yogev, et al.
Journal of Medical Virology|November 26, 2010
Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV replication in three older childrenBen Z Katz, Babak Salimi, Samantha L Gadd, et al.
The Pediatric Infectious Disease Journal|September 9, 2005
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of ageEllen Gould Chadwick, John H Rodman, Paula Britto, et al.
Journal of the Pediatric Infectious Diseases Society|December 1, 2015
Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract InfectionEvan J Anderson, Eric A F Simões, Jim P Buttery, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
AIDS Research and Human Retroviruses|March 11, 2008
Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremiaWilliam Borkowsky, Ram Yogev, Petronella Muresan, et al.
Pediatrics|February 3, 2005
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected childrenRita J Jeremy, Soyeon Kim, Molly Nozyce, et al.
Pediatrics|March 18, 2005
The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxisSharon Nachman, Philimon Gona, Wayne Dankner, et al.
The Pediatric Infectious Disease Journal|December 25, 2008
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patientsJennifer R King, Edward P Acosta, Ram Yogev, et al.
The Pediatric Infectious Disease Journal|May 18, 2016
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young AdultsMarc Foca, Ram Yogev, Andrew Wiznia, et al.
Pediatrics|March 12, 2008
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjectsXavier Saez-Llorens, Avy Violari, Dalubuhle Ndiweni, et al.
AIDS (London, England)|December 22, 2007
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week resultsEllen G Chadwick, Edmund V Capparelli, Ram Yogev, et al.
Journal of Medical Virology|November 26, 2010
Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV replication in three older childrenBen Z Katz, Babak Salimi, Samantha L Gadd, et al.
The Pediatric Infectious Disease Journal|September 9, 2005
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of ageEllen Gould Chadwick, John H Rodman, Paula Britto, et al.
Journal of the Pediatric Infectious Diseases Society|December 1, 2015
Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract InfectionEvan J Anderson, Eric A F Simões, Jim P Buttery, et al.
Pageof 13